Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Riboflavin 5'-Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.83 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.83 |
| ▸ | TST | Q16762 | 2/20 | 0.97 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.97 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.97 |
| ▸ | ESR1 | P03372 | 1/20 | 0.83 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.83 |
| ▸ | HTR2C | P28335 | 1/20 | 0.83 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.69 |
| ▸ | USP2 | O75604 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | HAT1 | O14929 | 4/20 | 0.69 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | RECQL | P46063 | 3/20 | 0.69 |
| ▸ | CASP7 | P55210 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | CASP1 | P29466 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin 5'-Phosphate SCHEMBL623880 | 0.99 | TST (0.98) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL8656633 | 0.99 | TST (0.98) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL26122 | 0.99 | TST (0.98) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL29456702 | 0.98 | TST (1.00) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL29839430 | 0.98 | TST (1.00) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL29738641 | 0.98 | TST (1.00) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL21899339 | 0.98 | TST (1.00) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL1078313 | 0.96 | TST (0.92) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL19816821 | 0.96 | TST (0.92) | TSTHSPD1HSPE1ESR1NR3C1 | |
| Riboflavin 5'-Phosphate SCHEMBL195609 | 0.94 | TST (0.88) | TSTHSPD1HSPE1ESR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746099-A | Eukaryotic semisynthetic organisms | 斯克利普斯研究所 | 2022-07-12 | — | — | CN | disclosed |
| EP-3150727-B1 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECH INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10227641-B2 | RNase H-based assays utilizing modified RNA monomers | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190002865-A1 | RNase H-Based Assays Utilizing Modified RNA Monomers | INTEGRATED DNA TECHNOLOGIES, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20170355978-A1 | RNase H-Based Assays Utilizing Modified RNA Monomers | INTEGRATED DNA TECHNOLOGIES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-9644198-B2 | RNase H-based assays utilizing modified RNA monomers | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| EP-3150727-A1 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | Integrated DNA Technologies Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2644710-B1 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECH INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9434988-B2 | RNase H-based assays utilizing modified RNA monomers | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2971072-A1 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | Integrated DNA Technologies Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2644709-A1 | RNase-H-based assays utilizing modified RNA monomers | Integrated Dna Technologies, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2644707-A1 | RNase-H-based assays utilizing modified RNA monomers | Integrated Dna Technologies, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2644710-A1 | RNase-H-based assays utilizing modified RNA monomers | Integrated Dna Technologies, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2279263-B1 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECH INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120258455-A1 | RNase H-Based Assays Utilizing Modified RNA Monomers | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2012135053-A2 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-2279263-A2 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | Integrated Dna Technologies, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100167353-A1 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20090325169-A1 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009135093-A2 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325169-A1 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | RNASEH1, RNASEL, RNASE1 | ADRB2 4738/4885ADRA1A 3886/4885TST 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.